Abogen announced the appointment of Dr. Li Weimin as President of Preclinical Research. He will comprehensively oversee the company’s preclinical R&D strategy and pipeline portfolio, accelerate the clinical translation of pipeline projects, and further drive Abogen’s innovative breakthroughs in RNA therapeutics on a global scale.Dr. Weimin Li has over 20 years of extensive experience in the biopharmaceutical industry. With a global strategic vision and proven R&D management capabilities, he has successively held senior management positions at leading global pharmaceutical companies, including Johnson & Johnson, AstraZeneca, and Takeda. His expertise spans multiple domains, including drug discovery, translational medicine, and early clinical development.Dr. Weimin Li possesses profound professional expertise and a proven track record of practical achievements in oncology, immunology, cell therapy, and other novel therapeutic modalities. He has been deeply involved in and advanced the early-stage development of multiple innovative drugs, facilitating their successful NDA/BLA approvals, including Zytiga, Erleada, Imfinzi, and Imjudo, among others.Dr. Yingbo, Founder, Chairman and CEO of Abogen, stated:“We are delighted to welcome Dr. Li Weimin to Abogen. Dr. Li brings exceptional R&D leadership and a proven track record in the successful development of multiple therapeutics. His addition will comprehensively strengthen pioneering innovation within our preclinical pipeline, enhance R&D decision-making efficacy, and inject robust momentum into the company’s innovation-driven growth. I look forward to working alongside Dr. Li to jointly advance the clinical translation of cutting-edge RNA technologies.”“Abogen has not only established a proprietary end-to-end technology platform but also achieved continuous R&D breakthroughs, demonstrating robust innovative vitality. I look forward to working alongside the team to further consolidate preclinical research, accelerate translational medicine initiatives, and help Abogen secure its position at the forefront of RNA R&D, ultimately translating advanced technologies into safer and more effective clinical outcomes.”About Us
Abogen Biosciences Co., Ltd. (abbreviated as "Abogen") is an innovative biopharmaceutical company focused on the research and development of messenger ribonucleic acid (mRNA) therapeutics. The company possesses an industry-leading, proprietary mRNA and nanoparticle delivery technology platform, and is one of the few mRNA therapeutics R&D enterprises in China with full value chain capabilities, encompassing every stage from mRNA design and formulation development to large-scale manufacturing. The company has established a robust product pipeline spanning multiple therapeutic areas, including cancer immunotherapy, autoimmune diseases, and infectious disease prevention and treatment.
